SVFC - IntelliCell BioSciences, Inc

[agemuwoy]

IntelliCell BioSciences, Inc. Appoints Dr. Sigmund Norr to Its Board of Advisors


NEW YORK, NY--(Marketwire - Oct 19, 2011) - IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today it has appointed pediatrician, Dr. Sigmund Norr to its Board of Advisors. Dr. Norr, of the Cleveland Clinic, joins ten other prominent doctors on the Company's Board of Advisors.

Sigmund Carl Norr, Ph.D., M.D., practices general pediatrics and serves as Section Head of Pediatrics at the Willoughby Hills Family Health Center. Prior to joining the Cleveland Clinic, Dr. Norr was Medical Director and staff physician at MEDGroup in Fairlawn, Ohio. Preceding that, Dr. Norr served in a number of roles with Ohio Permanente Medical Group, including Medical Director of the Alcohol Chemical Dependency Program, and Chief of the Department of Pediatric and Adolescent Medicine.

He is board-certified in pediatrics and addiction medicine. Dr. Norr received his undergraduate degree in biology from the University of Pittsburgh. He completed a doctorate in developmental cell biology at Case Western Reserve University and earned his medical degree from the University of Miami. He completed an internship and residency in pediatric medicine at Rainbow Babies and Children's Hospital in Cleveland, Ohio.

Dr. Norr is a member of the American Academy of Pediatrics. His specialty interests include ambulatory pediatrics and adolescent medicine, ADHD, asthma, and adolescent chemical dependency. He has published and spoken on the topics of neurobiology and cell biology.

"We welcome Dr. Norr aboard and look forward to what we're sure will be a substantive contribution to IntelliCell given his extensive knowledge of cell biology and pediatric medicine," stated IntelliCell Chairman and CEO, Dr. Steven Victor.

[ajalgsbt24]

NEW YORK, NY--(Marketwire - Oct 17, 2011) - IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) ("IntelliCell" or the "Company"), a leader in regenerative medicine and the manufacturing of stromal vascular fraction (SVF) containing adipose derived adult stem cells, announced today it has appointed media veteran, Jack Schneider to its Board of Advisors. Jack Schneider joins ten other luminaries on the Company's Board of Advisors.

Mr. Jack Schneider served as Managing Director of Allen & Co. LLC for more than 30 years. Mr. Schneider has also been on the Board of the National Mentoring Partnership for 12 years, and he has served as Chairman of the Buoniconti Fund to Cure Paralysis for 25 years. He serves on the Board of Autism Speaks. His addition to the IntelliCell team brings an unparalleled level of experience and new relationships to the company at a time when regenerative medicine could become the defining term for innovation and new forms of treatment in the fast evolving medical field. He also has a wealth of M&A experience from Allen & Co. and his long-term relationships with other leaders in forward-thinking communities concerned with neurological disorders opens many doors to new opportunities for IntelliCell.

"I am delighted that Jack Schneider has joined the Board of Advisors and I am sure that his wealth of knowledge and interest in Paralysis and Autism will help guide us into new and exciting frontiers regarding the use of our technology," stated IntelliCell Chairman and CEO, Dr. Steven Victor.

[AlbinaDuo9]

"I am excited about the technology of IntelliCell BioSciences as it pertains to possible treatments of paralysis and autism," according to Jack Schneider.

The use of autologous adipose (fat) stem cells for a growing variety of indications is a new and exciting frontier in medicine. In the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the US FDA published its laws on autologous stem cells the field has expanded rapidly. Currently, doctors, companies and researchers are studying the use of these adipose stem cells for aesthetics; the treatment of arthritis; and numerous orthopedic injuries such as knees, elbows, back, and shoulders; wound healing; congestive heart failure; gum regeneration and other ailments.

[Alekseysank]

IntelliCell BioSciences Out to Shake Up Regenerative Medicine With Disruptive Technology and Game Plan


LOS ANGELES, CA--(Marketwire - Sep 28, 2011) - Shares of the tightly held IntelliCell BioSciences, Inc. (OTCQB: SVFC) (PINKSHEETS: SVFC) have been starting to climb since announcing their arrival as a disruptive stem cell harvesting technology firm just a few short weeks ago. The regenerative medicine industry is starting to take notice, but it appears investors are too.

BioMedReports first told readers about this company in a report from the Rodman & Renshaw Conference, and shares have climbed from $3 to over $4 since then. Even in these very anemic market conditions, speculators are starting to take positions after hearing about the potential of the IntelliCell platform.

In addition, the Company just announced that they executed an exclusive supply and sale agreement with Millipore Corporation, a global leader in innovative tools and technologies for bio-manufacturing and life science research, to sell and distribute the guava? flow cytometry platform into the area of stromal vascular fraction.

[AlfredKa]

The market potential for IntelliCell BioSciences is far more attractive, and we are hearing rumors that various sports franchises may be looking to treat the injuries of pro athletes using the IntelliCell platform within the offices of their own team doctors. No surprise if true, since they have pro sports teams physicians on their advisory board.

The use of autologous adipose stem cells for a growing variety of indications may appear new and exciting in medicine here in the U.S, but the aesthetic world the use of autologous adipose stem cells has become widely accepted in Europe and Asia. Since the middle of 2009 when the U.S. FDA published its laws on autologous stem cells the field has expanded rapidly. If you are looking for a stem cell play that isn't going to make you wait 5+ years for FDA approval, this may be it.

A new report featuring more information about IntelliCell BioSciences, Inc. may be read at:

http://biomedreports.com/2011092879492/regenerative-medicine-industry-taking-notice-of-intellicell-biosciences.html

In addition, investors may access BioMedReports' new complete FDA Calendar and database of clinical trials and world-wide regulatory decisions for use as a tool in more profitable trading by visiting:

http://biomedreports.com/access-our-exclusive-fda-and-clinical-trials-calendars.html